Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 552 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR What’s Your Mantra? July 28, 2021 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are... September 30, 2019 Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... September 29, 2023 Load more HOT NEWS How and When to Wash Your Reusable Cloth Mask and When... Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up Thanks For Making This GivingTuesday Our Best One Yet! Our sun safety messaging tours the UK with the NIVEA Sun...
